CDTX (Cidara Therapeutics) Float Percentage Of Total Shares Outstanding : 99.78% (As of May. 06, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cidara Therapeutics's float shares is 12.52 Mil. Cidara Therapeutics's total shares outstanding is 12.55 Mil. Cidara Therapeutics's float percentage of total shares outstanding is 99.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cidara Therapeutics's Insider Ownership is 10.50%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cidara Therapeutics's Institutional Ownership is 62.75%.

Cidara Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cidara Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	12.52	/	12.55
	=	99.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cidara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

20D0:Germany 20D0:Germany

Address

6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121

Website

https://www.cidara.com

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Executives

Leslie Tari	officer: Chief Scientific Officer	C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Shane Ward	officer: CHIEF LEGAL OFFICER	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Taylor Sandison	officer: Chief Medical Officer	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein	director, officer: President & CEO	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Preetam Shah	officer: CFO & CBO	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala	officer: Chief Medical Officer	6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson	officer: Dir. of Finance & Controller	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston	director	C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder	director	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher	director	6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess	director	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121